← Back to Search

PRISM for Cancer (PRISM-AC Trial)

N/A
Waitlist Available
Led By Abby R Rosenberg, MD, MS, MA
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 12-24 years
Be younger than 65 years old
Must not have
Patient Refusal
Parent Refusal (if patient <18 years-old)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-months
Awards & highlights

Summary

This trial is testing whether the PRISM intervention can help adolescents and young adults with advanced cancer manage stress.

Who is the study for?
This trial is for adolescents and young adults aged 12-24 with advanced cancer, who can speak and read English or Spanish. They should be cognitively able to participate in interviews. It's not open to those whose parents refuse participation (if under 18) or if the patient themselves refuses.
What is being tested?
The PRISM intervention is being tested in this study across multiple sites. The goal of PRISM is to help these young individuals manage stress, improve resilience, and enhance their quality of life while dealing with advanced cancer.
What are the potential side effects?
Since PRISM focuses on stress management techniques rather than medication, traditional side effects are not expected. However, participants may experience emotional discomfort when discussing personal topics during sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 12 and 24 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have chosen not to participate in certain treatments.
Select...
My parents have not refused participation in the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PedsQL Generic Core and Cancer-Specific Quality of Life scores
Secondary study objectives
Connor Davidson Resilience Scale
Hope scale score
Hospital Anxiety and Depression Scale (HADS) score
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Promoting Resilience in Stress Management (PRISM)Experimental Treatment1 Intervention
Resilience Skills Training
Group II: Usual CareActive Control1 Intervention
Standard psychosocial care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Promoting Resilience in Stress Management (PRISM)
2020
N/A
~250

Find a Location

Who is running the clinical trial?

Pittsburgh Children's HospitalUNKNOWN
Children's Hospital Los AngelesOTHER
244 Previous Clinical Trials
5,072,872 Total Patients Enrolled
5 Trials studying Depression
1,116 Patients Enrolled for Depression
National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,806 Total Patients Enrolled
84 Trials studying Depression
66,238 Patients Enrolled for Depression

Media Library

Promoting Resilience in Stress Management (PRISM) Clinical Trial Eligibility Overview. Trial Name: NCT03668223 — N/A
Depression Research Study Groups: Promoting Resilience in Stress Management (PRISM), Usual Care
Depression Clinical Trial 2023: Promoting Resilience in Stress Management (PRISM) Highlights & Side Effects. Trial Name: NCT03668223 — N/A
Promoting Resilience in Stress Management (PRISM) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03668223 — N/A
~30 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top